Ryo Yamamoto, Kazuma Yamakawa, Akira Endo, Koichiro Homma, Yasunori Sato, Ryo Takemura, Takeshi Yamagiwa, Keiki Shimizu, Daiki Kaito, Masayuki Yagi, Taku Yonemura, Takayuki Shibusawa, Ginga Suzuki, Takahiro Shoji, Naoya Miura, Jiro Takahashi, Chihiro Narita, Saori Kurata, Kazunobu Minami, Takeshi Wada, Yoshihisa Fujinami, Yohei Tsubouchi, Mai Natsukawa, Jun Nagayama, Wataru Takayama, Ken Ishikura, Kyoko Yokokawa, Yasuo Fujita, Hirofumi Nakayama, Hideki Tokuyama, Kota Shinada, Takayuki Taira, Shoki Fukui, Noritaka Ushio, Masaki Nakane, Eisei Hoshiyama, Akihito Tampo, Hisako Sageshima, Hiroki Takami, Shinichi Iizuka, Hitoshi Kikuchi, Jun Hagiwara, Takashi Tagami, Yumi Funato, Junichi Sasaki, Study Group Er-Oxytrac
INTRODUCTION: Cardiac arrest is a critical condition, and patients often experience postcardiac arrest syndrome (PCAS) even after the return of spontaneous circulation (ROSC). Administering a restricted amount of oxygen in the early phase after ROSC has been suggested as a potential therapy for PCAS; however, the optimal target for arterial partial pressure of oxygen or peripheral oxygen saturation (SpO2 ) to safely and effectively reduce oxygen remains unclear. Therefore, we aimed to validate the efficacy of restricted oxygen treatment with 94%-95% of the target SpO2 during the initial 12 hours after ROSC for patients with PCAS...
September 15, 2023: BMJ Open